ArticleClinical kidney journal2016
Serum uric acid and AKI: is it time?
Article in Clinical kidney journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 14 citations in OpenAlex.
- Association between hyperuricemia and acute kidney injury in critically ill patients with sepsis.BMC nephrology · 2023Article
- Development of an acute kidney injury risk prediction model for patients undergoing extracorporeal membrane oxygenation.Heliyon · 2022Article
- Benefits of D-005, a lipid extract from Acrocomia crispa fruits, in the prevention of acute kidney njury induced by nephrotoxicity in rats.Jornal brasileiro de nefrologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a well-recognized complication in hospitalized patients, with associated mortality and morbidity. Studies that aim to prevent or reverse AKI using pharmacological and interventional therapies in clinical practice have been disappointing. Work is continuing to identify potentially modifiable risk factors for AKI. Early identification and modification of these risk factors may help prevent or favorably influence the outcome of AKI. The role of uric acid as a potential risk factor is being revisited in chronic kidney disease and AKI. Apart from the established crystal precipitation with profound hyperuricemia, various non-crystal mechanisms have also been proposed in the pathogenesis of AKI. The association of serum uric acid levels with the development of AKI has been reported in various clinical settings. Together, the results of these studies highlight hyperuricemia as a potential risk factor of AKI and the need for further work on this subject.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.